Quark Pharmaceuticals

Quark Pharmaceuticals was a private biotech company focused on developing RNA interference-based therapies targeting novel genes implicated in chronic and acute diseases. The company leveraged its proprietary BiFAR platform to identify new drug targets. It had collaborations with major pharma companies like Pfizer and academic institutions such as the University at Buffalo. Its clinical pipeline included candidates for hearing loss prevention, cancer therapy through hypoxia pathway modulation, dyslipidemia treatment, and several dermatological conditions. Most recent public information suggests the company ceased operations ("out of business"). Clinical results were not detailed in available sources.